City University of New York temporarily halted its probe into the alleged scientific misconduct of faculty member and Alzheimer’s researcher Hoau-Yan Wang, PhD, citing concerns about the integrity of the investigation. (New York Times, Science)
The EMBARK pivotal study of delandistrogene moxeparvovec (Elevidys) failed to meet its primary endpoint in Duchenne muscular dystrophy, Sarepta Therapeutics said. In June, the FDA granted accelerated approval to the one-time gene therapy.
Higher triglyceride levels were tied to lower dementia risk, prospective data from the ASPREE trial showed. (Neurology)
A virtual tai chi program improved cognition and executive function in older adults with mild cognitive impairment. (Annals of Internal Medicine)
Fine particulate matter in regional hot spots was tied to Parkinson’s risk among Medicare beneficiaries. (Neurology)
A 6-week cognitive behavioral therapy program with four booster sessions was superior to standard care alone in treating multiple sclerosis fatigue. (Journal of Neurology, Neurosurgery, and Psychiatry)
Systolic blood pressure variability in older age, but not in midlife, was linked with higher dementia risk. (JAMA Network Open)
Three rare genetic variants with large effects shed light on the pathology of migraine subtypes. (Nature Genetics)
The targeted C5 complement inhibitor zilucoplan (Zilbrysq) was approved to treat generalized myasthenia gravis, drugmaker UCB announced.
Adverse events in childhood were risk factors for primary headache disorders in adulthood, a meta-analysis suggested. (Neurology)
Please enable JavaScript to view the